razormetrics.com Open in urlscan Pro
2606:4700:20::681a:7e5  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Solutions
   * I am an Employer
   * I am a Health Plan
   * I am a Partner
 * for Employers
 * for Health Plans
 * Partnership Collective
   * About the Collective
   * Brokers
 * About
   * About RazorMetrics
   * The Platform
   * Events
   * Blog & News
   * Resource Library
   * Contact Us
 * Contact Us
 * ···

 * Solutions
   * I am an Employer
   * I am a Health Plan
   * I am a Partner
 * for Employers
 * for Health Plans
 * Partnership Collective
   * About the Collective
   * Brokers
 * About
   * About RazorMetrics
   * The Platform
   * Events
   * Blog & News
   * Resource Library
   * Contact Us
 * Contact Us
 * ···


COPAY ACCUMULATOR CONFUSION

 * RazorMetrics
 * May 17, 2024

Have you tried to read your annual health benefits handbook and given up after a
couple of pages? Most people just check their yearly deductible and total
out-of-pocket amounts but the formula behind that calculus is beyond the first
few pages. Health plans and employers that offer insurance collect
premiums, but they also try to share the direct costs through copays for doctor
appointments and medications.


SHARE THIS POST




Have you tried to read your annual health benefits handbook and given up after a
couple of pages? Most people just check their yearly deductible and total
out-of-pocket amounts but the formula behind that calculus is beyond the first
few pages. Health plans and employers that offer insurance collect
premiums, but they also try to share the direct costs through copays for doctor
appointments and medications. Healthcare cost-sharing mechanisms are mystifying,
and the back-and-forth policy changes from different administrations and the
courts do nothing to alleviate the confusion. A recent court ruling on “copay
accumulators” is a perfect example. 

Health insurers created copay accumulators in 2016 to minimize the impact of
drug manufacturer coupons on their total drug spending. Here is how it works:
the value of any copay assistance provided by drug manufacturer coupons is not
counted towards a patient’s deductible or out-of-pocket maximum. Patient
advocacy groups did not like this policy and sued. Since then, the regulatory
environment has been dynamic, to say the least.

Here’s a timeline:

January 2020: The Health and Human Services (HHS) finalized regulation on Copay
accumulator programs goes into effect. It permits accumulator programs only when
a generic medicine is available but not used. 

January 2021: HHS reversed course, allowing private health plans to apply copay
accumulators to manufacturer copay assistance regardless of a generic’s
availability.  

August 2022: Patient advocacy groups sued, arguing the 2021 final rule
conflicted with the Affordable Care Act’s statutory definition of “cost-sharing”
and was arbitrary and capricious.

September 2023: The U.S. District Court for the District of Columbia struck down
the 2021 final rule, agreeing with the plaintiffs that it was arbitrary and
capricious because it adopted different and contradictory readings of
the same statutory and regulatory text.

November 2023: HHS filed a motion in response to the court order, indicating the
agency would take no enforcement action on accumulators until new rules are
issued through rulemaking. 

December 2023: The District Court clarified its September 2023 vacatur of the
2021 final rule, stating that the 2020 prior rule allowed copay accumulators
to be used when a generic equivalent is available. 

January 2024: The Biden Administration confirmed this stance by withdrawing its
appeal to the September court ruling and effectively reinstated the 2020 NBPP
rules that require copay assistance to count towards cost-sharing limits if no
generic drug alternative is available, but no enforcement is intended. 

Present day: While the 2020 rule is legally in effect, the agencies do not
intend to enforce the generic exception, so it is unclear if the industry will
follow the 2021 rule or the 2020, meaning more lawsuits and rulemaking are
inevitable.

Why the Fighting?

From an insurance provider’s perspective, copay accumulators are a financial
management tool designed to ensure that the cost-sharing works as intended for
out-of-pocket calculations. The approach maintains plan integrity and avoids
unintended subsidization of high-cost medications. 

Employers, particularly those with self-funded health plans, have adopted copay
accumulator programs to mitigate the financial impact of high-cost prescriptions
and control rising health benefits costs. This practice, which prevents the
counting of manufacturer copay assistance towards deductibles, helps manage
premiums and maintain overall benefits for their workforce. According to Segal
Consulting, employers can save between 10% to 15% on prescription claims.

However, looking at copay accumulators from the patient’s side, especially those
dependent on high-cost specialty drugs, these programs may lead to significant
financial strain. Copay accumulators reset a patient’s contribution once the
copay assistance is exhausted, potentially increasing out-of-pocket expenses
mid-year. Here are two examples of how this has impacted people:

Mary’s situation:

Mary has multiple sclerosis, a chronic health condition. She found a
manufacturer coupon to cover $6,000 monthly medication costs for six months. Her
out-of-pocket costs were less over the six months, but when the coupon
expired, she faced the full medication cost. Without the copay accumulator, the
deductible would have been met, and she would have lower costs instead of higher
costs after the coupon. Further, over the six months, she had other health
expenses that she paid for. If she had not used the coupon, she would have met
her deductible after three months instead of six. The coupon + accumulator cost
her more out of pocket. 

Bill’s story:

Bill has rheumatoid arthritis, and he relied on a copay card to afford a
biologic medication costing over $5,000 per month. Mid-year, after the copay
assistance was exhausted, he owed the full amount because his payments did not
count toward the deductible due to the accumulator program. The sudden financial
burden forced him to switch to a less effective medication, negatively impacting
his health. 

Patient advocacy groups criticize copay accumulators for penalizing patients who
rely on manufacturer assistance to afford their medications. They claim that
these programs hurt patients relying on coupons to afford
necessary medications because once the coupon value is exhausted, the patient
sees a sudden increase in out-of-pocket expenses. Medication non-adherence goes
up, leading to serious health repercussions and, ultimately, higher healthcare
costs.

The Crohn’s and Colitis Foundation graphic shows how patients pay higher
out-of-pocket for their meds when an accumulator program is in place.

HealthTech to the Rescue 

In some cases, using a coupon saves patients money, but often, the total
out-of-pocket annual cost is higher. HealthTech companies like RazorMetrics are
developing algorithms to define strategic medication management, including what
coupons are potentially available and if they will lower or raise costs for a
patient depending on their plan’s copay accumulator policy. RazorMetrics’
proprietary technology optimizes prescription choices, ensuring affordability
without compromising care quality. 

Since many patients are unaware of an accumulator program’s impact until
they are suddenly faced with a hefty bill at the pharmacy, high-quality
communication with patients is needed to prevent an unpleasant shock. HealthTech
can mitigate the financial impact and help manage out-of-pocket expenses more
effectively, so patients are not left confused and hurt by the financial
hardship. Communication strategies with patients should include the following: 

 * Monthly Text / Email Including:
   * Copay Accumulator: Helps patients understand their health plan uses a copay
     accumulator and updates the patient each month on their drug coupon’s
     availability.
   * Deductible and Out-of-Pocket Max: Updates the patient on how much
     deductible and out-of-pocket max are left to help them plan their budget.
 * Manufacturer Coupon Options: Alert patients to coupon options that would
   decrease their annual costs as well as therapeutic alternatives that may
   offer similar efficacy at a lower cost.

As legislative and judicial decisions continue to shape copay policy, the role
of HealthTech companies is critical to quickly determine how the changes impact
annual out-of-pocket costs and maintain transparency. For employers and health
plans grappling with copay accumulator adjustments, partnering with
technology-driven firms like RazorMetrics offers a balanced approach to managing
healthcare costs while ensuring access to potential savings through manufacturer
coupons. RazorMetrics assists employers and health plans by offering software
solutions that provide transparency and predictability in patient’s healthcare
expenses.

PrevPreviousRazorMetrics Completes Annual SOC 2 Recertification

NextConsumer Behavior Impacted by High Drugs, Says New ReportNext


MORE TO EXPLORE

Article


CONSUMERS DON’T LIKE POLYPHARMACY

Polypharmacy, defined as taking five or more medications a month, may be
appropriate but it is not without risks. RazorMetrics’ report, the State of Drug
Access, 2024 found that almost 62% of consumers had trouble with polypharmacy
stating side effects, confusion, complicated regimens, and other problems.

RazorMetrics May 30, 2024
Press


CONSUMER BEHAVIOR IMPACTED BY HIGH DRUGS, SAYS NEW REPORT

RazorMetrics, a healthcare technology company focused on lowering drug costs for
health plans and self-funded employers, released their annual State of Drug
Access report. The report is based on the findings of a consumer survey
conducted through Pollfish, using a random sampling method of 1000 adults (18
years and older).

RazorMetrics May 21, 2024


STOP THE VICIOUS CYCLE OF INCREASING DRUG SPEND.

We're here to help.
GET STARTED NOW

RazorMetrics dramatically cuts prescription drug costs for self-funded
companies, health plans, and their employees or members. 

Linkedin Twitter Telegram


SOLUTIONS

 * for Employers
 * for Health Plans
 * for Partners


ABOUT

 * Welcome to RazorMetrics
 * The Platform
 * Events
 * Contact Us


RESOURCES

 * Resource Library
 * Blog & News


© COPYRIGHT 2024 RAZORMETRICS, INC. ALL RIGHTS RESERVED.


LEGAL & PRIVACY





We'd like to show you notifications for the latest news and updates.


AllowCancel